expresspharmaAugust 07, 2019
Tag: lupin , facility inspection , ANSM
The inspection closed with no critical or major observations
Drug firm Lupin on Tuesday said inspection of a unit of its Mandideep facility in Madhya Pradesh by the French National Agency for Medicines and Health Products Safety (ANSM) has been completed with no major observations.
The good manufacturing practices (GMP) inspection of company’s finished product manufacturing facility (Unit-1) at Mandideep by the ANSM has been completed, Lupin said in a statement.
The inspection was conducted between April 8 to April 12, 2019, it added.
"The ANSM inspection closed with no critical or major observations," Lupin said
By Press Trust of India
-----------------------------------------------------------------------
Editor's Note:
If you have any suggestion to the content,
please email: Julia.Zhang@ubmsinoexpo.com
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: